<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379508</url>
  </required_header>
  <id_info>
    <org_study_id>CLDT600A2409</org_study_id>
    <secondary_id>2007-000180-13</secondary_id>
    <nct_id>NCT01379508</nct_id>
  </id_info>
  <brief_title>Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept</brief_title>
  <official_title>OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety following the Roadmap
      Concept strategy with an initial monotherapy using either telbivudine or tenofovir in HBeAg
      negative CHB patients. The data from the study should allow for the validation of the Roadmap
      concept in a prospective manner, for both telbivudine and tenofovir treated HBeAg negative
      CHB patients. As part of a post-approval commitment to the European Health Authorities, the
      data will also be used to provide an optimized clinical treatment strategy for better
      clinical use of telbivudine in European HBeAg negative patients. Furthermore, the data from
      the study will contribute to a better scientific understanding, disease management and
      treatment of HBeAg negative CHB patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2011</start_date>
  <completion_date type="Actual">December 10, 2015</completion_date>
  <primary_completion_date type="Actual">December 10, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving HBV DNA &lt; 300 Copies/mL (51 IU/mL) at Week 52 (rITT Population) -</measure>
    <time_frame>week 52</time_frame>
    <description>The primary objective of the study is to compare the efficacy of Roadmap-Concept-based telbivudine treatment versus Roadmap-Concept-based tenofovir treatment in HBeAg-negative CHB patients. The rate of HBV DNA &lt; 300 copies/mL (51 IU/mL) at week 52 will be used for the comparison of the efficacy. The hypothesis is that the aggregated rate of HBV DNA &lt; 300 copies/mL (51 IU/mL) at week 52 of Telbivudine (ARM 1) is non-inferior to Tenofovir (ARM 2). For the &quot;treating missing as failure&quot; analysis, patients who came for their primary endpoint Week 52 visit within the ± 7-day window but not on the exact designated day of the visit were treated as &quot;missing data.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Secondary Efficacy Endpoints (rITT)</measure>
    <time_frame>week 24, 52, 104</time_frame>
    <description>To assess the antiviral efficacy, as evaluated by the percentage of patients achieving HBV DNA &lt;300 copies/mL (51 IU/mL), ALT normalization, HBsAg loss, HBsAg conversion, virologic breakthrough (VB) at study visit, cumulative VB by study defined study period, cumulative treatment-emergent resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Secondary Efficacy Endpoints at Week 156 (mITT)</measure>
    <time_frame>156 weeks</time_frame>
    <description>To assess the antiviral efficacy, as evaluated by the percentage of patients achieving HBV DNA &lt;300 copies/mL (51 IU/mL) at Week156, ALT normalization, HBsAg loss, development of HBsAg conversion , cumulative tx emergent resistance, HBV DNA &lt;300 copies/mL with HBV DNA &lt;7 log at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR Change From Baseline in Telbivudine Arm vs Tenofovir Arm Over the Course of the Study</measure>
    <time_frame>Baseline, 24 weeks, 52 weeks, 104 weeks, 156 weeks</time_frame>
    <description>eGFR changes were calculated using the Modification of Diet in Renal Disease (MDRD) formula: GFR = 186 x (sCr)^(-1.154) x (age)^-0.203 with Female: Multiply GFR by 0.742; Black: Multiply GFR by 1.210. sCr is Serum Creatinine in mg/dl (measured at each scheduled visit). Age in years at visit (=[sCr sample collection date -Date of birth]/365.25). Weight in kilograms, as measured at the visit or the closest previous visit Safety population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>telbivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telbivudine 600 mg tablet orally (p.o.) once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with tenofovir 300 mg tablets p.o. once daily for the remaining weeks of treatment. The investigator was to initiate tenofovir add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA &lt; 300 copies/mL at Week 24 were to continue to receive telbivudine monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tenofovir 300 mg tablets p.o. once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with telbivudine 600 mg tablet p.o. once daily for the remaining weeks of treatment. The investigator was to initiate telbivudine add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA &lt; 300 copies/mL at Week 24 were to continue to receive tenofovir monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telbivudine</intervention_name>
    <description>600 mg film-coated tablets taken as 600 mg once daily</description>
    <arm_group_label>telbivudine</arm_group_label>
    <other_name>LDT600</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir disoproxil fumarate</intervention_name>
    <description>300 mg tablets taken as 300 mg once daily</description>
    <arm_group_label>tenofovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female, at least 18 years of age

        Documented compensated HBeAg negative CHB defined by all of the following:

          -  Detectable serum HBsAg at screening visit and at least 6 months prior;

          -  HBeAg negative at the screening visit with positive HBeAb;

          -  Serum HBV DNA &gt; 2000 IU/mL Serum ALT level &gt; 1×ULN and &lt;10×ULN at screening visit;
             patient with normal ALT ≤1xULN at screening are eligible, with moderate liver
             inflammation or fibrosis, complensated liver sirrhosis, ALT level &gt;1xULN wtihin last 6
             months

        Exclusion Criteria:

          -  Co-infected with HCV, HDV or HIV.

          -  Received treatment of nucleoside or nucleotide drugs at any time

          -  Received IFN or other immunomodulatory treatment within six months before Screening

          -  Pregnant or nursing (lactating) women

          -  Clinical signs/symptoms of hepatic decompensation

          -  History of myopathy, myositis or persistent muscle weakness

          -  history of clinical and laboratory evidence of chronic renal insufficency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1413</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandroupolis</city>
        <state>Evros</state>
        <zip>681 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caserta</city>
        <state>CE</state>
        <zip>81100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119333</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tarragona</city>
        <state>Cataluña</state>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <state>TUR</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Diyarbakir</city>
        <zip>21280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <results_first_submitted>December 9, 2016</results_first_submitted>
  <results_first_submitted_qc>March 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2018</results_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LdT Mono at Week 24</title>
          <description>Patients who were initially treated with telbivudine and had hepatitis B virus deoxyribonucleic acid &lt; 300 copies/mL in their blood at Week 24 and continued to receive 600 mg telbivudine daily after Week 24</description>
        </group>
        <group group_id="P2">
          <title>LdT+TDF at Week 24</title>
          <description>Patients who were initially treated with telbivudine and had hepatitis B virus deoxyribonucleic acid &gt; 300 copies/mL in their blood at Week 24 and continued to receive 600 mg telbivudine daily and additional 300 mg tenofovir after Week 24.</description>
        </group>
        <group group_id="P3">
          <title>TDF Mono at Week 24</title>
          <description>Patients who were initially treated with tenofovir and had hepatitis B virus deoxyribonucleic acid &lt; 300 copies/mL in their blood at Week 24 and continued to receive 300 mg tenofovir daily after Week 24.</description>
        </group>
        <group group_id="P4">
          <title>TDF + LdT at Week 24</title>
          <description>Patients who were initially treated with tenofovir and had hepatitis B virus deoxyribonucleic acid &gt; 300 copies/mL in their blood at Week 24 and continued to receive 300 mg tenofovir and additional 600 mg telbivudine after Week 24.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment to Week 104</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Wk 24</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Exposure ≥ 52 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal lab value</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Period Weeks 109-156</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LdT Mono at Week 24</title>
          <description>Patients who had hepatitis B virus deoxyribonucleic acid &lt; 300 copies/mL in their blood at Week 24 continued to receive 600 mg telbivudine daily after Week 24</description>
        </group>
        <group group_id="B2">
          <title>LdT+TDF at Week 24</title>
          <description>Patients who were initially treated with telbivudine and had hepatitis B virus deoxyribonucleic acid &gt; 300 copies/mL in their blood at Week 24 and continued to receive 600 mg telbivudine daily and additional 300 mg tenofovir after Week 24.</description>
        </group>
        <group group_id="B3">
          <title>TDF Mono at Week 24</title>
          <description>Patients who were initially treated with tenofovir and had hepatitis B virus deoxyribonucleic acid &lt; 300 copies/mL in their blood at Week 24 and continued to receive 300 mg tenofovir daily after Week 24.</description>
        </group>
        <group group_id="B4">
          <title>TDF + LdT at Week 24</title>
          <description>Patients who were initially treated with tenofovir and had hepatitis B virus deoxyribonucleic acid &gt; 300 copies/mL in their blood at Week 24 and continued to receive 300 mg tenofovir and additional 600 mg telbivudine after Week 24.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="99"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="109"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="241"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 30 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 30 and 50 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 50 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV DNA</title>
          <units>log10 copies/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.887" spread="1.2862"/>
                    <measurement group_id="B2" value="7.769" spread="1.2502"/>
                    <measurement group_id="B3" value="5.838" spread="1.2464"/>
                    <measurement group_id="B4" value="7.938" spread="1.0709"/>
                    <measurement group_id="B5" value="5.887" spread="1.2862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV DNA levels &lt; or ≥ 7 log 10 copies/mL at baseline.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 7 log 10 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="171"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 7 log 10 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with alanine aminotransferase (ALT) - Multiples of upper limits of normal (ULN)</title>
          <description>Serum ALT normalization is an important clinically relevant efficacy endpoint. Elevated serum ALT levels are thought to reflect underlying hepatitis disease activity (i.e. active liver inflammation). Correspondingly, ALT normalization is an accepted therapeutic goal in hepatitis studies as it is thought to reflect a substantial reduction in hepatic disease activity.Measurement at baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≤ 1 × ULN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 1 × - &lt; 2 × ULN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 × - &lt; 5 × ULN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 × or more ULN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with aspartate aminotransferase (AST) - Multiples of upper limits of normal (ULN)</title>
          <description>Measurment at baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≤ 1 × ULN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 1 × - &lt; 2 × ULN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 × - &lt; 5 × ULN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 × or more ULN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving HBV DNA &lt; 300 Copies/mL (51 IU/mL) at Week 52 (rITT Population) -</title>
        <description>The primary objective of the study is to compare the efficacy of Roadmap-Concept-based telbivudine treatment versus Roadmap-Concept-based tenofovir treatment in HBeAg-negative CHB patients. The rate of HBV DNA &lt; 300 copies/mL (51 IU/mL) at week 52 will be used for the comparison of the efficacy. The hypothesis is that the aggregated rate of HBV DNA &lt; 300 copies/mL (51 IU/mL) at week 52 of Telbivudine (ARM 1) is non-inferior to Tenofovir (ARM 2). For the &quot;treating missing as failure&quot; analysis, patients who came for their primary endpoint Week 52 visit within the ± 7-day window but not on the exact designated day of the visit were treated as &quot;missing data.&quot;</description>
        <time_frame>week 52</time_frame>
        <population>Roadmap intent-to-treat (rITT) population consisted of patients in the ITT population who did not discontinue before Wk 24 and did not receive add-on. The total of the mono and combination arms were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LdT Overall</title>
            <description>Ldt Mono and LdT + TDF combined</description>
          </group>
          <group group_id="O2">
            <title>TDF Overall</title>
            <description>TDF mono and TDF + LdT combined</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving HBV DNA &lt; 300 Copies/mL (51 IU/mL) at Week 52 (rITT Population) -</title>
          <description>The primary objective of the study is to compare the efficacy of Roadmap-Concept-based telbivudine treatment versus Roadmap-Concept-based tenofovir treatment in HBeAg-negative CHB patients. The rate of HBV DNA &lt; 300 copies/mL (51 IU/mL) at week 52 will be used for the comparison of the efficacy. The hypothesis is that the aggregated rate of HBV DNA &lt; 300 copies/mL (51 IU/mL) at week 52 of Telbivudine (ARM 1) is non-inferior to Tenofovir (ARM 2). For the &quot;treating missing as failure&quot; analysis, patients who came for their primary endpoint Week 52 visit within the ± 7-day window but not on the exact designated day of the visit were treated as &quot;missing data.&quot;</description>
          <population>Roadmap intent-to-treat (rITT) population consisted of patients in the ITT population who did not discontinue before Wk 24 and did not receive add-on. The total of the mono and combination arms were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Missing DNA data at Wk 52=failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0"/>
                    <measurement group_id="O2" value="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imputing +/- 7 days DNA for Wk 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9"/>
                    <measurement group_id="O2" value="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imputing LOCF DNA for Wk 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4"/>
                    <measurement group_id="O2" value="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imputing within +28d DNA for Wk 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7"/>
                    <measurement group_id="O2" value="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing DNA data at Wk 52=failure: To evaluate the primary objective, Mantel-Haenszel weighted estimates approach (stratified by HBV DNA level (&lt; 7 log10 copies/mL or ≥ 7 log10 copies/mL) and ALT (&lt; 3×ULN or ≥ 3×ULN) at baseline) was employed to assess the proportion of patients (response rate) who achieve HBV DNA &lt; 300 copies/mL after 52 weeks treatment in each treatment arm, as well as the difference in proportions (telbivudine – tenofovir arm) and the 95% CI of the difference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was derived if the lower limit of two-sided 95% CI for the difference lied above the pre-determined non-inferiority margin (-10%).</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Imputing +/- 7 days DNA for Wk 52: To evaluate the primary objective, Mantel-Haenszel weighted estimates approach (stratified by HBV DNA level (&lt; 7 log10 copies/mL or ≥ 7 log10 copies/mL) and ALT (&lt; 3×ULN or ≥ 3×ULN) at baseline) was employed to assess the proportion of patients (response rate) who achieve HBV DNA &lt; 300 copies/mL after 52 weeks treatment in each treatment arm, as well as the difference in proportions (telbivudine – tenofovir arm) and the 95% CI of the difference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was derived if the lower limit of two-sided 95% CI for the difference was above the pre-determined non-inferiority margin (-10%).</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Imputing LOCF DNA for wk 52: d/c for non response prior to Wk 52: Treating missing as failure for patients who discontinued prior to Week 52 due to unsatisfactory therapeutic effect and imputing missing with LOCF for other patients</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was derived if the lower limit of two-sided 95% CI for the difference lied above the pre-determined non-inferiority margin (-10%).</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Imputing within +28d DNA for wk52: d/c for non response &lt;28 days from Wk 52:Treating missing as failure for patients who discontinued prior to Week 52 due to unsatisfactory therapeutic effect and imputing missing with the earliest available assessment within the 28-day window starting from the scheduled Week 52 date for other patients (if no such assessment is available, treated as failure)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was derived if the lower limit of two-sided 95% CI for the difference lied above the pre-determined non-inferiority margin (-10%).</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.3</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Secondary Efficacy Endpoints (rITT)</title>
        <description>To assess the antiviral efficacy, as evaluated by the percentage of patients achieving HBV DNA &lt;300 copies/mL (51 IU/mL), ALT normalization, HBsAg loss, HBsAg conversion, virologic breakthrough (VB) at study visit, cumulative VB by study defined study period, cumulative treatment-emergent resistance</description>
        <time_frame>week 24, 52, 104</time_frame>
        <population>Roadmap intent-to-treat (rITT) population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LdT Mono at Week 24</title>
            <description>Patients who had hepatitis B virus deoxyribonucleic acid &lt; 300 copies/mL in their blood at Week 24 continued to receive 600 mg telbivudine daily after Week 24</description>
          </group>
          <group group_id="O2">
            <title>LdT+TDF at Week 24</title>
            <description>Patients who were initially treated with telbivudine and had hepatitis B virus deoxyribonucleic acid &gt; 300 copies/mL in their blood at Week 24 and continued to receive 600 mg telbivudine daily and additional 300 mg tenofovir after Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LdT Overall</title>
            <description>Ldt Mono and LdT + TDF combined</description>
          </group>
          <group group_id="O4">
            <title>TDF Mono at Week 24</title>
            <description>Patients who were initially treated with tenofovir and had hepatitis B virus deoxyribonucleic acid &lt; 300 copies/mL in their blood at Week 24 and continued to receive 300 mg tenofovir daily after Week 24.</description>
          </group>
          <group group_id="O5">
            <title>TDF + LdT at Week 24</title>
            <description>Patients who were initially treated with tenofovir and had hepatitis B virus deoxyribonucleic acid &gt; 300 copies/mL in their blood at Week 24 and continued to receive 300 mg tenofovir and additional 600 mg telbivudine after Week 24.</description>
          </group>
          <group group_id="O6">
            <title>TDF Overall</title>
            <description>TDF mono and TDF + LdT combined</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Secondary Efficacy Endpoints (rITT)</title>
          <description>To assess the antiviral efficacy, as evaluated by the percentage of patients achieving HBV DNA &lt;300 copies/mL (51 IU/mL), ALT normalization, HBsAg loss, HBsAg conversion, virologic breakthrough (VB) at study visit, cumulative VB by study defined study period, cumulative treatment-emergent resistance</description>
          <population>Roadmap intent-to-treat (rITT) population was analyzed.</population>
          <units>percentage of particiipants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBV DNA &lt;300 Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="94.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="80.5" lower_limit="72.0" upper_limit="87.4"/>
                    <measurement group_id="O4" value="99.1" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="89.7" lower_limit="82.8" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA &lt;300 Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="59.1" upper_limit="78.7"/>
                    <measurement group_id="O2" value="76.2" lower_limit="52.8" upper_limit="91.8"/>
                    <measurement group_id="O3" value="70.8" lower_limit="61.5" upper_limit="79.0"/>
                    <measurement group_id="O4" value="74.5" lower_limit="65.1" upper_limit="82.5"/>
                    <measurement group_id="O5" value="81.8" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O6" value="75.2" lower_limit="66.4" upper_limit="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA &lt;300 Week 24 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="81.4" lower_limit="73.0" upper_limit="88.1"/>
                    <measurement group_id="O4" value="100.0" lower_limit="96.6" upper_limit="100.0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="90.6" lower_limit="83.8" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA &lt;300 Wk104 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" lower_limit="84.9" upper_limit="96.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="83.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="93.8" lower_limit="87.7" upper_limit="97.5"/>
                    <measurement group_id="O4" value="99.1" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="99.1" lower_limit="95.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT Normalization Wk 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="70.9" upper_limit="92.8"/>
                    <measurement group_id="O2" value="83.3" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O3" value="83.8" lower_limit="72.9" upper_limit="91.6"/>
                    <measurement group_id="O4" value="82.5" lower_limit="70.1" upper_limit="91.3"/>
                    <measurement group_id="O5" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O6" value="82.8" lower_limit="71.3" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT Normalization Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="55.4" upper_limit="82.1"/>
                    <measurement group_id="O2" value="72.2" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O3" value="70.6" lower_limit="58.3" upper_limit="81.0"/>
                    <measurement group_id="O4" value="61.4" lower_limit="47.6" upper_limit="74.0"/>
                    <measurement group_id="O5" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O6" value="64.1" lower_limit="51.1" upper_limit="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT Normalization Wk 52 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="75.7" upper_limit="95.5"/>
                    <measurement group_id="O2" value="83.3" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O3" value="86.8" lower_limit="76.4" upper_limit="93.8"/>
                    <measurement group_id="O4" value="87.7" lower_limit="76.3" upper_limit="94.9"/>
                    <measurement group_id="O5" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O6" value="87.5" lower_limit="76.8" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT Normalization Wk 104 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" lower_limit="80.8" upper_limit="97.8"/>
                    <measurement group_id="O2" value="83.3" lower_limit="58.6" upper_limit="96.4"/>
                    <measurement group_id="O3" value="89.7" lower_limit="79.9" upper_limit="95.8"/>
                    <measurement group_id="O4" value="86.0" lower_limit="74.2" upper_limit="93.7"/>
                    <measurement group_id="O5" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O6" value="85.9" lower_limit="75.0" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg loss Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg loss Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg conversion Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3.2"/>
                    <measurement group_id="O4" value="0" lower_limit="00" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg conversion Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum virol break BaseL to Wk 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.9"/>
                    <measurement group_id="O2" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum virol break Wk 24 to Wk 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.7" upper_limit="9.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="2.7" lower_limit="0.6" upper_limit="7.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum virol break Wk 52 to Wk 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="6.1" upper_limit="20.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="9.7" lower_limit="5.0" upper_limit="16.8"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="1.7" lower_limit="0.2" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum virol break BaseLto Wk 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="7.7" upper_limit="23.0"/>
                    <measurement group_id="O2" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O3" value="12.4" lower_limit="6.9" upper_limit="19.9"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="1.7" lower_limit="0.2" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum vir break BL to Wk24 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.9"/>
                    <measurement group_id="O2" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum virol break Wk 24 to Wk 52 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.7" upper_limit="9.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="2.7" lower_limit="0.6" upper_limit="7.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum virol break Wk52-Wk104 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="6.1" upper_limit="20.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="9.7" lower_limit="5.0" upper_limit="16.8"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="1.7" lower_limit="0.2" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum virol break BLto Wk 104 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="7.7" upper_limit="23.0"/>
                    <measurement group_id="O2" value="4.8" lower_limit="0.1" upper_limit="23.8"/>
                    <measurement group_id="O3" value="12.4" lower_limit="6.6" upper_limit="19.9"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="1.7" lower_limit="0.2" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum tx emergent resistance Wk 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.7" upper_limit="9.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="2.7" lower_limit="0.6" upper_limit="7.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ccum tx emergent resistance Wk 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="4.1" upper_limit="17.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="7.4" lower_limit="3.3" upper_limit="14.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum tx emergent resist Wk52 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.7" upper_limit="9.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="2.7" lower_limit="0.6" upper_limit="7.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum tx emergent resist Wk 104 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="4.1" upper_limit="17.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16.1"/>
                    <measurement group_id="O3" value="7.4" lower_limit="3.3" upper_limit="14.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="28.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;7 log at BL HBV DNA &lt;300 Wk52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="85.3" upper_limit="97.8"/>
                    <measurement group_id="O2" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                    <measurement group_id="O3" value="92.5" lower_limit="84.4" upper_limit="97.2"/>
                    <measurement group_id="O4" value="95.0" lower_limit="87.7" upper_limit="98.6"/>
                    <measurement group_id="O5" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O6" value="95.2" lower_limit="88.1" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;7 log HBV DNA &lt;300 Wk104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="56.7" upper_limit="78.6"/>
                    <measurement group_id="O2" value="50.0" lower_limit="6.8" upper_limit="93.2"/>
                    <measurement group_id="O3" value="67.5" lower_limit="56.1" upper_limit="77.6"/>
                    <measurement group_id="O4" value="76.3" lower_limit="65.4" upper_limit="85.1"/>
                    <measurement group_id="O5" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                    <measurement group_id="O6" value="75.9" lower_limit="65.3" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;7 log HBV DNA &lt;300 Wk 52 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="90.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="97.5" lower_limit="91.3" upper_limit="99.7"/>
                    <measurement group_id="O4" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;7 log HBV DNA &lt;300 Wk 104 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="83.6" upper_limit="97.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="92.5" lower_limit="84.4" upper_limit="97.2"/>
                    <measurement group_id="O4" value="98.8" lower_limit="93.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O6" value="98.8" lower_limit="93.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Secondary Efficacy Endpoints at Week 156 (mITT)</title>
        <description>To assess the antiviral efficacy, as evaluated by the percentage of patients achieving HBV DNA &lt;300 copies/mL (51 IU/mL) at Week156, ALT normalization, HBsAg loss, development of HBsAg conversion , cumulative tx emergent resistance, HBV DNA &lt;300 copies/mL with HBV DNA &lt;7 log at Baseline</description>
        <time_frame>156 weeks</time_frame>
        <population>The modified ITT (mITT) population consisted of all patients in ITT population who were eligible and enrolled into the extension.</population>
        <group_list>
          <group group_id="O1">
            <title>LdT Mono at Week 24</title>
            <description>Patients who had hepatitis B virus deoxyribonucleic acid &lt; 300 copies/mL in their blood at Week 24 continued to receive 600 mg telbivudine daily after Week 24</description>
          </group>
          <group group_id="O2">
            <title>LdT+TDF at Week 24</title>
            <description>Patients who were initially treated with telbivudine and had hepatitis B virus deoxyribonucleic acid &gt; 300 copies/mL in their blood at Week 24 and continued to receive 600 mg telbivudine daily and additional 300 mg tenofovir after Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LdT Overall</title>
            <description>Ldt Mono and LdT + TDF combined</description>
          </group>
          <group group_id="O4">
            <title>TDF Mono at Week 24</title>
            <description>Patients who were initially treated with tenofovir and had hepatitis B virus deoxyribonucleic acid &lt; 300 copies/mL in their blood at Week 24 and continued to receive 300 mg tenofovir daily after Week 24.</description>
          </group>
          <group group_id="O5">
            <title>TDF + LdT at Week 24</title>
            <description>Patients who were initially treated with tenofovir and had hepatitis B virus deoxyribonucleic acid &gt; 300 copies/mL in their blood at Week 24 and continued to receive 300 mg tenofovir and additional 600 mg telbivudine after Week 24.</description>
          </group>
          <group group_id="O6">
            <title>TDF Overall</title>
            <description>TDF mono and TDF + LdT combined</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Secondary Efficacy Endpoints at Week 156 (mITT)</title>
          <description>To assess the antiviral efficacy, as evaluated by the percentage of patients achieving HBV DNA &lt;300 copies/mL (51 IU/mL) at Week156, ALT normalization, HBsAg loss, development of HBsAg conversion , cumulative tx emergent resistance, HBV DNA &lt;300 copies/mL with HBV DNA &lt;7 log at Baseline</description>
          <population>The modified ITT (mITT) population consisted of all patients in ITT population who were eligible and enrolled into the extension.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBV DNA &lt; 300 Week 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" lower_limit="9.2" upper_limit="29.5"/>
                    <measurement group_id="O2" value="11.8" lower_limit="1.5" upper_limit="36.4"/>
                    <measurement group_id="O3" value="16.5" lower_limit="9.1" upper_limit="26.5"/>
                    <measurement group_id="O4" value="13.9" lower_limit="7.2" upper_limit="23.5"/>
                    <measurement group_id="O5" value="20.0" lower_limit="2.5" upper_limit="55.6"/>
                    <measurement group_id="O6" value="14.6" lower_limit="8.0" upper_limit="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA &lt; 300 Wk156 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="78.1" upper_limit="95.3"/>
                    <measurement group_id="O2" value="100.0" lower_limit="80.5" upper_limit="100.0"/>
                    <measurement group_id="O3" value="91.1" lower_limit="82.6" upper_limit="96.4"/>
                    <measurement group_id="O4" value="100.0" lower_limit="95.4" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.00" lower_limit="95.9" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT normalization Wk 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="4.8" upper_limit="30.3"/>
                    <measurement group_id="O2" value="6.7" lower_limit="0.2" upper_limit="31.9"/>
                    <measurement group_id="O3" value="12.0" lower_limit="4.5" upper_limit="24.3"/>
                    <measurement group_id="O4" value="10.5" lower_limit="2.9" upper_limit="24.8"/>
                    <measurement group_id="O5" value="28.6" lower_limit="3.7" upper_limit="71.0"/>
                    <measurement group_id="O6" value="13.3" lower_limit="5.1" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT normalization Wk 156 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="69.7" upper_limit="95.2"/>
                    <measurement group_id="O2" value="93.3" lower_limit="68.1" upper_limit="99.8"/>
                    <measurement group_id="O3" value="88.0" lower_limit="75.7" upper_limit="95.5"/>
                    <measurement group_id="O4" value="86.8" lower_limit="71.9" upper_limit="95.6"/>
                    <measurement group_id="O5" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O6" value="86.7" lower_limit="73.2" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBSAg loss/ seroconversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="19.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="30.8"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum VB Wk104-156 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="8.0" upper_limit="27.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="19.5"/>
                    <measurement group_id="O3" value="12.7" lower_limit="6.2" upper_limit="22.0"/>
                    <measurement group_id="O4" value="1.3" lower_limit="0" upper_limit="6.9"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="30.8"/>
                    <measurement group_id="O6" value="1.1" lower_limit="0.0" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum VB BL to Wk 156 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="11.7" upper_limit="33.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="19.5"/>
                    <measurement group_id="O3" value="16.5" lower_limit="9.1" upper_limit="26.5"/>
                    <measurement group_id="O4" value="1.3" lower_limit="0" upper_limit="6.9"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="30.8"/>
                    <measurement group_id="O6" value="1.1" lower_limit="0.0" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum tx emerg resist Week 156 LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="6.3" upper_limit="25.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="19.5"/>
                    <measurement group_id="O3" value="10.8" lower_limit="4.8" upper_limit="20.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="30.8"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA &lt; 300 Wk156 &lt;7 log at BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="8.4" upper_limit="30.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O3" value="16.7" lower_limit="7.9" upper_limit="29.3"/>
                    <measurement group_id="O4" value="11.7" lower_limit="4.8" upper_limit="22.6"/>
                    <measurement group_id="O5" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                    <measurement group_id="O6" value="12.9" lower_limit="5.7" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA &lt;300 Wk156 &lt;7 log LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2" lower_limit="76.1" upper_limit="95.6"/>
                    <measurement group_id="O2" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="88.9" lower_limit="77.4" upper_limit="95.8"/>
                    <measurement group_id="O4" value="100.0" lower_limit="94.0" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cum tx-emerg resist Wk156 &lt;7log LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="2.4" upper_limit="20.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O3" value="8.2" lower_limit="2.3" upper_limit="19.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="84.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>eGFR Change From Baseline in Telbivudine Arm vs Tenofovir Arm Over the Course of the Study</title>
        <description>eGFR changes were calculated using the Modification of Diet in Renal Disease (MDRD) formula: GFR = 186 x (sCr)^(-1.154) x (age)^-0.203 with Female: Multiply GFR by 0.742; Black: Multiply GFR by 1.210. sCr is Serum Creatinine in mg/dl (measured at each scheduled visit). Age in years at visit (=[sCr sample collection date -Date of birth]/365.25). Weight in kilograms, as measured at the visit or the closest previous visit Safety population.</description>
        <time_frame>Baseline, 24 weeks, 52 weeks, 104 weeks, 156 weeks</time_frame>
        <population>Safety population consisted of patients who received at least 1 dose of study drug and had 1 post-baseline safety assessment. Numbers in parentheses represent the number of participants who met the criteria for the measurement in the 2 LDT arms, LDT Overall, 2 TDF arms, TDF Overall, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>LdT Mono at Week 24</title>
            <description>Patients who had hepatitis B virus deoxyribonucleic acid &lt; 300 copies/mL in their blood at Week 24 continued to receive 600 mg telbivudine daily after Week 24</description>
          </group>
          <group group_id="O2">
            <title>LdT+TDF at Week 24</title>
            <description>Patients who were initially treated with telbivudine and had hepatitis B virus deoxyribonucleic acid &gt; 300 copies/mL in their blood at Week 24 and continued to receive 600 mg telbivudine daily and additional 300 mg tenofovir after Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LdT Overall</title>
            <description>Ldt Mono and LdT + TDF combined</description>
          </group>
          <group group_id="O4">
            <title>TDF Mono at Week 24</title>
            <description>Patients who were initially treated with tenofovir and had hepatitis B virus deoxyribonucleic acid &lt; 300 copies/mL in their blood at Week 24 and continued to receive 300 mg tenofovir daily after Week 24.</description>
          </group>
          <group group_id="O5">
            <title>TDF + LdT at Week 24</title>
            <description>Patients who were initially treated with tenofovir and had hepatitis B virus deoxyribonucleic acid &gt; 300 copies/mL in their blood at Week 24 and continued to receive 300 mg tenofovir and additional 600 mg telbivudine after Week 24.</description>
          </group>
          <group group_id="O6">
            <title>TDF Overall</title>
            <description>TDF mono and TDF + LdT combined</description>
          </group>
        </group_list>
        <measure>
          <title>eGFR Change From Baseline in Telbivudine Arm vs Tenofovir Arm Over the Course of the Study</title>
          <description>eGFR changes were calculated using the Modification of Diet in Renal Disease (MDRD) formula: GFR = 186 x (sCr)^(-1.154) x (age)^-0.203 with Female: Multiply GFR by 0.742; Black: Multiply GFR by 1.210. sCr is Serum Creatinine in mg/dl (measured at each scheduled visit). Age in years at visit (=[sCr sample collection date -Date of birth]/365.25). Weight in kilograms, as measured at the visit or the closest previous visit Safety population.</description>
          <population>Safety population consisted of patients who received at least 1 dose of study drug and had 1 post-baseline safety assessment. Numbers in parentheses represent the number of participants who met the criteria for the measurement in the 2 LDT arms, LDT Overall, 2 TDF arms, TDF Overall, respectively</population>
          <units>mL/min/1.73 m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 change (97,22,119,108,11,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="12.815"/>
                    <measurement group_id="O2" value="-12.06" spread="14.394"/>
                    <measurement group_id="O3" value="-1.07" spread="14.076"/>
                    <measurement group_id="O4" value="-2.41" spread="14.885"/>
                    <measurement group_id="O5" value="-7.17" spread="15.368"/>
                    <measurement group_id="O6" value="-2.85" spread="14.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 change(97,22,119,108,11,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" spread="18.842"/>
                    <measurement group_id="O2" value="-6.80" spread="17.229"/>
                    <measurement group_id="O3" value="2.96" spread="19.064"/>
                    <measurement group_id="O4" value="-2.70" spread="18.636"/>
                    <measurement group_id="O5" value="-8.39" spread="10.479"/>
                    <measurement group_id="O6" value="-3.22" spread="18.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 change(97,22,119,108,11,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.19" spread="16.583"/>
                    <measurement group_id="O2" value="-5.77" spread="15.943"/>
                    <measurement group_id="O3" value="3.16" spread="16.947"/>
                    <measurement group_id="O4" value="-3.83" spread="15.157"/>
                    <measurement group_id="O5" value="-8.69" spread="15.632"/>
                    <measurement group_id="O6" value="-4.28" spread="15.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 change(62,17,79,79,10,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.07" spread="16.777"/>
                    <measurement group_id="O2" value="-10.89" spread="14.993"/>
                    <measurement group_id="O3" value="3.99" spread="18.104"/>
                    <measurement group_id="O4" value="-5.34" spread="13.393"/>
                    <measurement group_id="O5" value="-6.67" spread="11.905"/>
                    <measurement group_id="O6" value="-5.49" spread="13.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline actual(98,22,120,109,11,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.71" spread="16.422"/>
                    <measurement group_id="O2" value="109.79" spread="19.560"/>
                    <measurement group_id="O3" value="97.47" spread="17.936"/>
                    <measurement group_id="O4" value="95.91" spread="16.396"/>
                    <measurement group_id="O5" value="94.50" spread="17.558"/>
                    <measurement group_id="O6" value="95.78" spread="16.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 actual(97,22,119,108,11,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.43" spread="16.434"/>
                    <measurement group_id="O2" value="97.73" spread="17.690"/>
                    <measurement group_id="O3" value="96.67" spread="16.603"/>
                    <measurement group_id="O4" value="93.61" spread="18.500"/>
                    <measurement group_id="O5" value="87.33" spread="16.854"/>
                    <measurement group_id="O6" value="93.03" spread="18.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 actual(97,22,119,108,11,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.18" spread="20.257"/>
                    <measurement group_id="O2" value="102.99" spread="19.425"/>
                    <measurement group_id="O3" value="100.70" spread="20.054"/>
                    <measurement group_id="O4" value="93.32" spread="18.880"/>
                    <measurement group_id="O5" value="86.12" spread="14.233"/>
                    <measurement group_id="O6" value="92.66" spread="18.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 actual (97,22,119,108,11,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.20" spread="16.287"/>
                    <measurement group_id="O2" value="104.02" spread="18.201"/>
                    <measurement group_id="O3" value="100.90" spread="16.643"/>
                    <measurement group_id="O4" value="92.19" spread="18.240"/>
                    <measurement group_id="O5" value="85.81" spread="13.099"/>
                    <measurement group_id="O6" value="91.60" spread="17.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 actual(62,17,79,79,10,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.33" spread="18.505"/>
                    <measurement group_id="O2" value="100.70" spread="20.029"/>
                    <measurement group_id="O3" value="101.20" spread="18.712"/>
                    <measurement group_id="O4" value="88.83" spread="16.773"/>
                    <measurement group_id="O5" value="87.93" spread="13.280"/>
                    <measurement group_id="O6" value="88.73" spread="16.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LdT Mono at Week 24</title>
          <description>LdT Mono at Week 24</description>
        </group>
        <group group_id="E2">
          <title>LdT + TDF at Week 24</title>
          <description>LdT + TDF at Week 24</description>
        </group>
        <group group_id="E3">
          <title>TDF Mono at Week 24</title>
          <description>TDF Mono at Week 24</description>
        </group>
        <group group_id="E4">
          <title>TDF + LdT at Week 24</title>
          <description>TDF + LdT at Week 24</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Metastases to abdominal wall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychogenic pain disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Crystalluria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nephroptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

